OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $32.3333.

Several analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OnKure Therapeutics in a report on Wednesday, October 8th. Zacks Research downgraded shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of OnKure Therapeutics in a report on Tuesday, August 26th.

Hedge Funds Weigh In On OnKure Therapeutics

Large investors have recently made changes to their positions in the company. ADAR1 Capital Management LLC acquired a new position in shares of OnKure Therapeutics in the 1st quarter valued at $43,000. XTX Topco Ltd acquired a new position in shares of OnKure Therapeutics in the 2nd quarter valued at $25,000. Bailard Inc. acquired a new position in shares of OnKure Therapeutics in the 2nd quarter valued at $34,000. Rangeley Capital LLC acquired a new position in shares of OnKure Therapeutics in the 2nd quarter valued at $71,000. Finally, Affinity Asset Advisors LLC lifted its stake in shares of OnKure Therapeutics by 173.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 394,159 shares of the company’s stock valued at $1,695,000 after purchasing an additional 250,000 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

OnKure Therapeutics Trading Up 0.3%

Shares of NASDAQ OKUR opened at $2.89 on Wednesday. The company has a 50 day simple moving average of $2.62 and a two-hundred day simple moving average of $2.59. The stock has a market cap of $39.10 million, a price-to-earnings ratio of -0.60 and a beta of 0.43. OnKure Therapeutics has a 12 month low of $1.70 and a 12 month high of $19.40.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.09. Analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.